Poseida Therapeutics (PSTX)
(Delayed Data from NSDQ)
$2.76 USD
+0.06 (2.22%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $2.76 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Poseida Therapeutics, Inc. [PSTX]
Reports for Purchase
Showing records 1 - 20 ( 45 total )
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from our HCW @ Home Fireside Chat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional Evidence for P-KLKB1-101?s Therapeutic Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Astellas Putting More Chips on the Table; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways From Gene Therapy RD Day; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional Signal of P-BCMA-ALLO1?s Broad Potential in Multiple Myeloma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Inflection Points in Back Half of the Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Era of Allogeneic CAR-T on the Horizon; Higher $20 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Another Big Pharma?s Interest Speaks of the Potential of Poseida?s Platforms; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updates from CAR-T Programs Remain On Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Catalysts From Cell Therapy Franchise in 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Ushering in a New Era of Cell and Gene Therapies; Initiate With Buy and a $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Poseida Therapeutics, Inc.
Industry: Medical - Dental Supplies
Dropping Coverage Due to Stryker Acquisition
Provider: Roth Capital Partners, Inc.
Company: Poseida Therapeutics, Inc.
Industry: Medical - Dental Supplies
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Poseida Therapeutics, Inc.
Industry: Medical - Dental Supplies
Company: Poseida Therapeutics, Inc.
Industry: Medical - Dental Supplies
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.